1521-1878/asset/olbannerleft.gif?v=1&s=2845fffff50a3ee70a98eae52f73644aabfc6da8)
What the papers say
Cancer therapy: switching off oncogenes
Article first published online: 21 JAN 2003
DOI: 10.1002/bies.10238
Copyright © 2003 Wiley Periodicals, Inc.
1521-1878/asset/cover.gif?v=1&s=f234907c8865cfc8a1848f6eb81952e44c16f2af "BioEssays")
Additional Information
How to Cite
Pompetti, F., Pilla, D. and Giancola, R. (2003), Cancer therapy: switching off oncogenes. Bioessays, 25: 104–107. doi: 10.1002/bies.10238
Publication History
- Issue published online: 21 JAN 2003
- Article first published online: 21 JAN 2003
- Abstract
- References
- Cited By
Abstract
Cancer derives from a cell clone that has accumulated genetic and epigenetic changes that influence its phenotype and finally enable it to escape from the normal controls of proliferation. A recent paper shows that, in myc-induced tumours, the inactivation of this oncogene produces the regression of the tumours and the differentiation of the tumour cells into mature osteocytes.1 In addition, a further reactivation of myc in these cells does not restore the malignant phenotype but induces apoptosis. This discovery could lead to an innovative therapeutic strategy. BioEssays 25:104–107, 2003. © 2003 Wiley Periodicals, Inc.